Wrap Text
Audited Annual Consolidated Financial Statements for the Financial year ended 31 March 2026, Distribution of Integrated Annual Report and Notice of Annual General Meeting, and Availability of B-BBEE Annual Compliance Report
CILO CYBIN HOLDINGS LIMITED
Incorporated in the Republic of South Africa
(Registration number 2022/320351/06)
JSE Share code: CCC ISIN: ZAE000310397
Listed on the General Segment of the JSE
Issuer with a weighted voting structure
(“Cilo Cybin” or “the Company” or “the Group”)
AUDITED ANNUAL CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 MARCH
2026, DISTRIBUTION OF INTEGRATED ANNUAL REPORT AND NOTICE OF ANNUAL GENERAL MEETING, AND
AVAILABILITY OF B-BBEE ANNUAL COMPLIANCE REPORT
KEY FINANCIAL HIGHLIGHTS
- Group total revenue decreased by 18,65% to R28,814,412 (2025: R35,420,493)
- Group profit for the year decreased from a profit of R20,052,871 in 2025 to a loss of R239,732,145
- Headline earnings and earnings per share decreased by 1111% to a loss per share of 95.90 cents
(2025: 9.49 cents profit*)
- Dividend per share declared remained unchanged (2025: Nil)
*The consolidated comparative numbers for 2025 differ from those previously reported by the Company in the prior
year due to the application of IFRS accounting to the acquisition of Cilo Cybin Pharmaceutical Proprietary Limited and
the impact of reverse acquisition accounting arising from the transaction.
Cilo Cybin is a South African pharmaceutical and medicinal cannabis-focused company listed on the General Segment
of the Main Board of the JSE Limited (“JSE”). The Group is focused on developing and commercialising pharmaceutical
and medicinal cannabis products in regulated healthcare markets.
In September 2025, Cilo Cybin concluded the acquisition of 100% of Cilo Cybin Pharmaceutical Proprietary Limited
(“CCP”) for an aggregate purchase consideration of R845 million, settled through the issue of Cilo Cybin shares. The
transaction resulted in CCP becoming a wholly owned subsidiary and provided Cilo Cybin with an operating
pharmaceutical platform aligned with its strategy of expanding its presence in the medicinal cannabis and
pharmaceutical sectors.
The acquisition was a reverse listing in terms of IFRS, resulting in CCP being deemed the accounting acquirer and the
Company the accounting acquiree, since Cilo Cybin did not meet the definition of a "business" in terms of IFRS 3.
Accordingly, any excess of the fair value of the shares issued by the accounting acquirer over the fair value of the
accounting acquiree’s recognisable net assets was expensed, since the excess fair value represents a share-based
payment made in exchange for obtaining a listing. This resulted in the group having to recognise a once off IFRS 2
share-based payment/ listing expense in the Statement of Profit and Loss of R217 480 665.
INTEGRATED ANNUAL REPORT
Cilo Cybin shareholders are advised that the integrated annual report for the year ended 31 March 2026 (“IAR”) has
been distributed to shareholders today, Monday, 7 September and will be available on the Company’s website at
www.cilocybin.com/financial-information
Electronic copies of the IAR can also be requested from the Company Secretary at no charge via e-mail at
sascha@ramirez.co.za and are available for inspection (by appointment) at the Company’s registered office during
office hours.
NOTICE OF ANNUAL GENERAL MEETING
Notice is hereby given that the annual general meeting of shareholders of the Company (“AGM”) will be held at 10:00
on Wednesday, 7 October 2026, entirely by electronic communication, to consider and, if deemed fit, to pass with or
without modification, the ordinary and special resolutions set out in the notice of AGM (“Notice”), which is contained
in the IAR.
The salient information pertaining to the AGM is set out below:
Issuer name Cilo Cybin Holdings Limited
Type of instrument Ordinary shares and Class A ordinary shares
ISIN number ZAE00031039
JSE code CCC
Meeting type Annual General Meeting
Meeting venue Virtual
Record date – to determine which shareholders are entitled to Friday, 28 August 2026
receive the Notice
Publication/Distribution date Monday, 7 September 2026
Last day to trade – to determine eligible shareholders that may Tuesday, 29 September 2026
attend, speak and vote at the AGM
Record date – to determine eligible shareholders that may attend, Friday, 2 October 2026
speak and vote at the AGM
Meeting deadline date – forms of proxy for the AGM to be lodged, 10:00 on Monday, 5 October 2026
for administrative purposes
AGM date Wednesday, 7 October 2026
Results of AGM released on SENS on or before Wednesday, 7 October 2026
Website link www.cilocybin.com/holdings
RESULTS ANNOUNCEMENT
This content of this announcement is the responsibility of the board of directors of the Company (“Board”). The results
announcement does not contain full or complete details of the audited consolidated financial statements for the year
ended 31 March 2026 (“2026 AFS”). Any investment decision by investors and/or shareholders should be based on
consideration of the 2026 AFS, which are available as detailed below. The information contained in this results
announcement has not been reviewed or reported on by the Company’s auditors.
The 2026 AFS have been audited by the Company’s auditors, Nexia SAB&T, who expressed an unmodified audit
opinion thereon. The audit report, together with the 2026 AFS included in the integrated annual report, are available
on the JSE cloudlink: https://senspdf.jse.co.za/documents/2026/jse/isse/ccce/FY26.pdf and has also been published
on the Company’s website at: www.cilocybin.com/financial-information
B-BBEE ANNUAL COMPLIANCE REPORT
Shareholders are advised that the annual compliance report for Cilo Cybin, prepared pursuant to section 13G(2) of the
Broad-Based Black Economic Empowerment Amendment Act No. 46 of 2013, is available on the Company’s website
www.cilocybin.com/financial-information
Directors:
Executive
Gabriel Christiaan Theron (Chief Executive Officer)
Jessica Moodley Theron (Acting Chief Financial Officer)
Non-executive
Sakekile Baduza* (Lead Independent Director)
Dr Tham Seng Kong (Chairman)
Daktuk Mohd Razef Abdullah*
Hendrik Jacobus (Henk) Vivier*
* Independent
Registered office
The registered office, which is also the principal place of business, is:
23 Sterling Road, Unit E4 The Point Office Park, Samrand, 0157
Centurion
7 September 2026
Sponsor
Merchantec Capital
Date: 07/09/2026 05:26:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
